1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Organon: Adalimumab Sales Won’t Surpass $100m In 2023, Despite US Launch

US-Based Firm In ‘Fight’ For Formulary Position, Eyeing Further BD Opportunities

 
• By Dean Rudge

Organon has provided a relatively clear guide for how its planned launch of a US biosimilar to AbbVie’s Humira in July will impact its top line in 2023, with further detail on the coming years.

Investment maturity success as a business concept for growing wealth as a small tree gradually turning into a mature flying arrow plant as a financial metaphor for a successful investing on white.
• Source: Shutterstock

Continuing to expect a gradual market formation in 2023 for biosimilars to AbbVie’s Humira (adalimumab), alongside only a partial year of revenue contribution given its anticipated 1 July launch date, Organon believes its global Hadlima (adalimumab) sales will represent “no more than about 1.5% of our consolidated 2023 revenue.”

Disclosing a full-year 2023 revenue guide of $6.15bn-$6

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Teva And Alvotech Celebrate Interchangeability For US Ustekinumab

 
• By Dave Wallace

The market for biosimilar rivals to Stelara continues to be hotly contested in the US, with partners Teva and Alvotech claiming a boost from an interchangeability designation at the same time as Biocon Biologics highlighted fresh market access agreements.

Amgen Biosimilars Continue Surge Ahead Of Imminent Denosumab Competition

 
• By Dean Rudge

Thanks to its efficient development pipeline, sales of Amgen’s biosimilars neared $750m for the first three months of the year, offering some comfort as the firm gears up for the loss of exclusivity for its denosumab franchise.

Tofidence And Tariffs - Organon Discusses Exposure Of Its Biosimilars Business

 
• By Dave Wallace

During Organon’s first-quarter results call, CEO Kevin Ali discussed the exposure of the biosimilars business to US tariffs, as well as pointing to the recent acquisition of Tofidence (tocilizumab-bavi) from Biogen as an opportunity for growth, as the segment saw a double-digit decline.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

More from Products